Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Metabolism

Targeting BCAA Catabolism to Treat Obesity-Associated Insulin Resistance

  1. Meiyi Zhou1,
  2. Jing Shao1,
  3. Cheng-Yang Wu2,
  4. Le Shu3,
  5. Weibing Dong1,
  6. Yunxia Liu1,
  7. Mengping Chen1,
  8. R. Max Wynn2,
  9. Jiqiu Wang4,
  10. Ji Wang1,
  11. Wen-Jun Gui2,
  12. Xiangbing Qi5,
  13. Aldons J. Lusis6,
  14. Zhaoping Li7,
  15. Weiqing Wang4,
  16. Guang Ning4,
  17. Xia Yang3,
  18. David T. Chuang2,
  19. Yibin Wang8 and
  20. Haipeng Sun1,8⇑
  1. 1Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Hongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  2. 2Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX
  3. 3Department of Integrative Biology and Physiology, University of California at Los Angeles, Los Angeles, CA
  4. 4Department of Endocrinology and Metabolism, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  5. 5Chemistry Center, National Institute of Biological Science, Beijing, China
  6. 6Departments of Medicine, Microbiology, and Human Genetics, University of California at Los Angeles, Los Angeles, CA
  7. 7Department of Clinical Nutrition, University of California at Los Angeles, Los Angeles, CA
  8. 8Departments of Anesthesiology, Medicine, and Physiology, University of California at Los Angeles, Los Angeles, CA
  1. Corresponding author: Haipeng Sun, sun.haipeng{at}yahoo.com
  1. M.Z., J.S., C.-Y.W., and L.S. contributed equally to this work.

Diabetes 2019 Sep; 68(9): 1730-1746. https://doi.org/10.2337/db18-0927
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Integrative genomic analyses associate the BCAA catabolic pathway with IR-related traits in human populations. A: The integrative genomics workflow we used to investigate the association of BCAAs with IR-related traits in humans. Specifically, human GWAS were integrated with eQTLs and coexpression networks matched by tissue, and then analyzed using the Mergeomics pipeline in order to identify coexpression modules that showed significant genetic association with IR-related clinical traits. Coexpression modules with significant over-representation of BCAA genes among the module genes were then annotated as BCAA modules. B: Number of BCAA modules with significant trait association (FDR <5% or P < 0.05, as assessed by using MSEA in the Mergeomics pipeline). Numbers in the bars indicate the fold enrichment of BCAA modules among all significant coexpression modules for the corresponding trait. Statistical significance of enrichment of BCAA modules among all significant modules was determined by using the Fisher exact test. Details of enrichment test are in Supplementary Table 2. C: Comparison of tissue origin distribution of BCAA modules and all coexpression modules significantly associated with fasting insulin and IR (BMI unadjusted) at FDR <5% and P < 0.05. Significance of differences in the mean correlation strength between gene categories was calculated by using the Student t test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    The BCAA catabolic pathway shows a strong correlation with IR in a mouse population. A: Comparison of correlation strengths of the expression of BCAA pathway genes, non-BCAA amino acid pathway genes, and all genes with IR-related traits in mice. The correlation data between tissue-specific expression profiling and measurements of clinical traits were extracted from the HMDP, which contains ∼100 strains of genetically divergent mice fed an HFD. The mean and SE of the absolute values of Pearson correlations between each gene within a gene category (BCAA, non-BCAA, all genes) and a trait are shown. The significance of differences in the mean correlation strength between gene categories was calculated by using the Student t test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. B: Correlation of individual BCAA catabolic genes in different tissues for fasting glucose, fasting insulin, and HOMA-IR in HMDP mice fed an HFD. Red indicates a positive correlation, whereas blue indicates a negative correlation. *P < 0.05 and **P < 0.05 after Bonferroni correction for the number of genes and traits.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    Systematic downregulation of the BCAA catabolic pathway leads to a BCAA catabolic defect in ob/ob mice. A: Quantitative PCR results of BCAA catabolic genes in white adipose tissue, skeletal muscle, and liver in lean wild-type (WT) mice (n = 4) and ob/ob mice (n = 4) deprived of food for 6 h. B: Illustration of the partial BCAA catabolic process with enzymes, intermediates, and derivatives. C: Relative levels of BCAAs and their metabolites in plasma and tissues of lean WT mice (n = 6–8) and ob/ob mice (n = 8). Male mice, age 14 weeks, were deprived of food for 6 h before being sacrificed. D: Serum concentrations of BCAAs and BCKAs in lean WT mice (n = 8) and ob/ob mice (n = 10). Male mice, age 8 weeks, were deprived of food from 8:00 a.m. to 5:00 p.m. and then supplied with chow diet for 1 hour. Blood (100 μL) was collected at 6:00 p.m. from the orbital sinus by using capillary tubes for serum collection. *P < 0.05 and **P < 0.01 vs. WT mice. ΚΙC, α-ketoisocaproic acid; KIV, α-ketoisovaleric acid; KMV, α-keto-β-methylvaleric acid.

  • Figure 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4

    The BCKDK inhibitor restores BCAA catabolism and attenuates IR in ob/ob mice. ob/ob mice were treated with the vehicle (Ctrl) or BT2 (at 10 weeks [A, B, and E] or 4–6 weeks [C and D]) by oral gavage (n = 6 mice in each group). We analyzed BCKD activity in various tissues (A), fasting plasma levels of BCAAs (B, left) and BCKAs (B, right), glucose tolerance test results (C), insulin tolerance test results (D), fasting plasma insulin level (E), body weight (F), and food intake (G). *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.0001 vs. Ctrl. ΚΙC, α-ketoisocaproic acid; KIV, α-ketoisovaleric acid; KMV, α-keto-β-methylvaleric acid; WAT, white adipose tissue.

  • Figure 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5

    Altering BCAA intake affects IR in ob/ob mice. ob/ob mice were fed an NPD (20% protein by weight) or an LPD (6% protein by weight) for 4 weeks beginning at 10 weeks of age. For the BCAA group (LPD + BCAA), supplementation of BCAAs in drinking water (3 mg/mL) was started after mice had eaten the LPD for 2 weeks and lasted 2 weeks. We analyzed fasting plasma levels of BCAAs and metabolites (n = 8 mice; *P < 0.05 vs. NPD; &P < 0.05 vs. LPD) (A), glucose tolerance test results (n = 6–13 mice; **P < 0.01, LPD vs. NPD; &P < 0.05, LPD vs. LPD + BCAA) (B), insulin tolerance test results (n = 6 mice in each group; *P < 0.05, ***P < 0.001, LPD vs. NPD; &P < 0.05, LPD vs. LPD + BCAA) (C), fasting plasma insulin levels (n = 8–12 mice; *P < 0.05; &P < 0.05) (D), and body weight (n = 14 mice in each group; **P < 0.01).

  • Figure 6
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6

    BCAAs and BCKAs contribute to impaired insulin signaling in ob/ob mice. A–C: Representative immunoblots for specific proteins, created by using tissue lysates from skeletal muscle, liver, and white adipose tissue of mice without or with insulin (Ins) injection for 10 min following 6 h of food deprivation. ob/ob mice were fed an NPD (20% protein by weight) or an LPD (6% protein by weight) for 4 weeks beginning at 10 weeks of age (A). BCAA supplementation (LPD + BCAA or LPD/amino acids) in drinking water (3 mg/mL) was started after mice had consumed the LPD for 2 weeks and lasted 2 weeks (B). ob/ob mice were treated with the vehicle (Ctrl) or BT2 by oral gavage for 5 weeks (C). The graphs below the immunoblots in A–C present densitometric values of the bands. D–F: Representative immunoblots for specific proteins, created by using cell lysates. 3T3-L1 cells were treated with FBS- and BCAA-free DMEM for 1–2 h before BCAA (500 μmol/L), BCKA (500 μmol/L), or rapamycin (100 nmol/L) treatment for 1 h (D and F) or various times (E), followed by insulin treatment (10 nmol/L) for 1 h (D). *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.0001.

  • Figure 7
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7

    The BCKDK inhibitor enhances BCAA catabolism and attenuates IR in DIO mice. DIO mice were treated with the vehicle (Ctrl) or BT2 by oral gavage for 8 weeks (n = 7 mice in each group). We analyzed BCKD activity in various tissues (A), fasting plasma levels of BCAAs (B, left) and BCKAs (B, right), glucose tolerance test results (C), insulin tolerance test results (D), fasting plasma insulin level (E), and body weight (F). *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.0001, all vs. Ctrl. ΚΙC, α-ketoisocaproic acid; KIV, α-ketoisovaleric acid; KMV, α-keto-β-methylvaleric acid.

PreviousNext
Back to top
Diabetes: 68 (9)

In this Issue

September 2019, 68(9)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Targeting BCAA Catabolism to Treat Obesity-Associated Insulin Resistance
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Targeting BCAA Catabolism to Treat Obesity-Associated Insulin Resistance
Meiyi Zhou, Jing Shao, Cheng-Yang Wu, Le Shu, Weibing Dong, Yunxia Liu, Mengping Chen, R. Max Wynn, Jiqiu Wang, Ji Wang, Wen-Jun Gui, Xiangbing Qi, Aldons J. Lusis, Zhaoping Li, Weiqing Wang, Guang Ning, Xia Yang, David T. Chuang, Yibin Wang, Haipeng Sun
Diabetes Sep 2019, 68 (9) 1730-1746; DOI: 10.2337/db18-0927

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Targeting BCAA Catabolism to Treat Obesity-Associated Insulin Resistance
Meiyi Zhou, Jing Shao, Cheng-Yang Wu, Le Shu, Weibing Dong, Yunxia Liu, Mengping Chen, R. Max Wynn, Jiqiu Wang, Ji Wang, Wen-Jun Gui, Xiangbing Qi, Aldons J. Lusis, Zhaoping Li, Weiqing Wang, Guang Ning, Xia Yang, David T. Chuang, Yibin Wang, Haipeng Sun
Diabetes Sep 2019, 68 (9) 1730-1746; DOI: 10.2337/db18-0927
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Research Design and Methods
    • Results
    • Discussion
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Ncor2/PPARα-Dependent Upregulation of MCUb in the Type 2 Diabetic Heart Impacts Cardiac Metabolic Flexibility and Function
  • Role of the Neutral Amino Acid Transporter SLC7A10 in Adipocyte Lipid Storage, Obesity, and Insulin Resistance
  • Heme Oxygenase-1 Regulates Ferrous Iron and Foxo1 in Control of Hepatic Gluconeogenesis
Show more Metabolism

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.